Call-for-Papers | JACC: CardioOncology

Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is growing science in the bi-directional relationship between cardiovascular disease and cancer. JACC: CardioOncology is launching a call for submissions for a special focus issue examining the basic, translational, and clinical science in the emerging area of Bi-directional Cardio-Oncology. Innovative original scientific investigat

Read the full article here

Source: www.jacc.org

Categories: Oncologists1, General Medicine News

Tweets with this article

Oncology Advance

🚨 Call for Submissions! 🚨JACC: CardioOncology is looking for studies exploring the mechanistic and epidemiologic overlap between cancer and cardiovascular disease, as well as novel therapies targeting both. Submit your work today! https://t.co/FJDBY0Ur6K https://t.co/tVNs7aFioA

Related Articles

New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers

A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.

OncLive.com January 21, 2025

IMMagine-1: Preliminary phase II results of anitocabtagene autoleucel in patients with triple-class exposed RRMM

We summarize key preliminary results from the phase II IMMagine-1 study investigating the efficacy and safety of the BCMA-directed CAR T-cell therapy anitocabtagene autoleucel in…

Multiple Myeloma Hub January 21, 2025

Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets

Whereas immunotherapies have revolutionized the treatment of different solid and hematologic cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCL) is limited, due to a…

Haematologica January 21, 2025

ALLG trial: Ibrutinib plus R-mini-CHOP in older patients with newly diagnosed DLBCL

We summarize key results from the phase II ALLG study of ibrutinib + R-mini-CHOP in older patients with newly diagnosed DLBCL.

Lymphoma Hub January 21, 2025

Insights into mRNA expression in ADC targets in metastatic breast cancer

Kristien Borremans, PhD, KU Leuven, Louvain, Belgium, discusses findings from the UPTIDER trial (NCT04531696), which analyzed the mRNA expression of 72 antibody-drug conjugate (ADC) targets…

VJ Oncology January 21, 2025

Advances in precision medicine for breast cancer in 2025

Jenna Canzoniero, MD, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, provides an overview of recent advancements in precision medicine for breast cancer, emphasizing the…

VJ Oncology January 21, 2025

FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL

On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with bendamustine and rituximab…

VJHemOnc January 21, 2025

World Cancer Day 2025: International Journal of Cancer

The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.

International Journal of Cancer January 21, 2025

Trump orders US to leave World Health Organization

Trump has long been critical of how the Geneva-based institution handled the Covid-19 pandemic.

The Lancet Oncology January 21, 2025

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

OncLive.com January 21, 2025